Intellectual Property India Publishes Patent Application for 'Nucleic Acids Encoding Tgf-Beta Inhibitor And Il-12 And Uses Thereof' Filed by Kalivir Immunotherapeutics, Inc.

MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517036506 A) filed by Kalivir Immunotherapeutics, Inc., Pittsburgh, on April 15, for 'nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof.'

Inventor(s) include Thorne, Stephen Howard; and Zhang, Mingrui.

The application for the patent was published on May 30, under issue no. 22/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. Compositions described herein are further described for use in the treatment of cancer."

The patent application was internationally filed on Oct. 18, 2023, under International application No.PCT/US2023/077151.

Disclaimer: Curated by HT Syndication.